Progression
The cancer is growing or spreading despite treatment, or after it. Progression usually means the current drug has stopped working and it is time to switch to the next line.
RECIST defines progression as at least a 20% increase in the sum of target-lesion diameters (and at least 5 mm absolute), or the appearance of any new lesion; clinical progression (worsening symptoms) can also count. Progression triggers the move from first-line to second-line therapy and, increasingly, a repeat biopsy or liquid biopsy to see what resistance mechanism has emerged. Time to progression is the basis of progression-free survival, the commonest primary endpoint in trials, and 'pseudoprogression', an apparent enlargement caused by immune cells flooding a tumour, can mislead early scans during immunotherapy.
Pages like this
not linked directly; found by shared links- TermDuration of response
Shares Complete response, Partial response, Progression-free survival (PFS).
- TermProgressive disease and radiographic progression
Shares RECIST, Lines of therapy, Progression-free survival (PFS).
- IdeaValidate real-world progression against central imaging review
Shares RECIST, Progression-free survival (PFS).
- TermSurrogate endpoint
- TermCross-resistance
Shares Lines of therapy, Drug resistance (primary and acquired).
- TermRelapsed / refractory (R/R)
Shares Lines of therapy, Drug resistance (primary and acquired).
- IdeaMake clonal clearance, not tumour shrinkage, a trial endpoint
Shares RECIST, Progression-free survival (PFS).
- IdeaStructured, coded radiology reports for cancer response instead of free text
Shares RECIST, Progression-free survival (PFS).